| Literature DB >> 31086610 |
Shuichi Hamada1, Miyuki Shigano1, Satoru Kawakami2, Maya Ueda3, Hajime Sui4, Katsuya Yamada5, Soichiro Hagio6, Ayaka Momonami7, Akihisa Maeda8, Yukari Terashima9, Wakako Ohyama10, Takeshi Morita11, Makoto Hayashi12.
Abstract
BACKGROUND: The repeated-dose liver micronucleus (RDLMN) assay is an effective and important in vivo test for detecting genotoxic compounds, particularly for those that require metabolic activation to show genotoxicity. In a collaborative study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/The Japanese Environmental Mutagen Society (JEMS) - Mammalian Mutagenicity Study Group (MMS), micronucleus induction of 22 chemicals with the RDLMN assay employing the collagenase digestion method was examined and reported on. Recently, we have developed a method which enables retrospective evaluation of micronucleus induction in formalin-fixed liver tissues (the formalin-fixed method) obtained in general toxicity studies completed in the past. Using this method, we were able to easily evaluate clastogenic potential of chemicals from the formalin-fixed tissues obtained in the general toxicity studies.In this study, to evaluate the usefulness of the formalin-fixed method, we have conducted a liver micronucleus assay using the formalin-fixed liver samples obtained from the above collaborative study (18 of 22 test chemicals) and carried out a comparison with the results obtained by the collagenase digestion method.Entities:
Keywords: Collagenase; Formalin-fixed tissue; Hepatocyte; Liver; Micronucleus assay
Year: 2019 PMID: 31086610 PMCID: PMC6507131 DOI: 10.1186/s41021-019-0128-5
Source DB: PubMed Journal: Genes Environ ISSN: 1880-7046
Chemical profiles used in the collaborative study by CSGMT/JEMS MMS
| Group | Chemical | Abbreviation | CAS no. | Chemical class |
|---|---|---|---|---|
| Group A | Dimethylnitrosoamine | DMN | 62–75-9 | nitroso compound |
| NPYR | 930–55-2 | nitroso compound | ||
| NDPA | 621–64-7 | nitroso compound | ||
| 2,4-Dinitrotoluene | 2,4-DNT | 121–14-2 | aromatic nitro compound | |
| Quinoline | QUN | 91–22-5 | heterocyclic compound | |
| DAB | 60–11-7 | azo compound | ||
| 2-Nitropropane | 2-NP | 79–46-9 | alkyl nitro compound | |
| Monocrotaline | MCT | 315–22-0 | alkaloid | |
| NMOR | 59–89-2 | nitroso compound | ||
| 2-Acetylaminofluorene | 2-AAF | 53–96-3 | aromatic amine | |
| Sudan I (C.I.solvent yellow 14) | Sudan I | 842–07-9 | azo compound | |
| Thioacetamide | TAA | 62–55-5 | thioamide | |
| Group B | Cyclophosphamide H2O | CP | 6055-19-2 | bis compound |
| Potassium bromate | KBrO3 | 7758-01-2 | inorganic metal compound | |
| MNNG | 70–25-7 | nitroso compound | ||
| Methyl methanesulfonate | MMS | 66–27-3 | alkyl sulfonate | |
| Group C | Clofibrate | CFB | 637–07-0 | chlorophenoxy compound |
| Methapyrilene HCl | MP | 135–23-9 | ethylene diamine |
Group A: Genotoxic hepatocarcinogens, Group B: genotoxic carcinogens but not liver targeted, Group C: nongenotoxic hepatocarcinogens
Fig. 1Comparison of RDLMN assay results of formalin-fixed method and collagenase digestion method using Group A chemicals. Incidences of MNHEPs (%); Comparison between formalin-fixed method (A) and collagenase digestion method reported by Hamada et al. [1] (B) in rats treated with Group A chemicals for 14 or 28 days. As for the 28-day RDLMN assay of NDPA using collagenase digestion method, it was conducted by Kissei Pharmaceutical Co., Ltd. as a collaborative study by CSGMT/JEMS MMS immediately after publication of a report by Hamada et al. [1]. Values are presented as the mean and SD. Differences in the incidences of MNHEPs between the test and vehicle control groups were analyzed by the Kastenbaum and Bowman test at significance levels of 5 and 1% (*: P < 0.05, **: P < 0.01). Differences in the incidences of mitotic phase cells between the test and vehicle control groups were analyzed by Dunnett’s multiple comparison test at significance levels of 5 and 1% (#: P < 0.05, ##: P < 0.01). Group A: genotoxic hepatocarcinogen
Fig. 2Comparison of RDLMN assay results of formalin-fixed method and collagenase digestion method using Group B chemicals. Incidences of MNHEPs (%); Comparison between formalin-fixed method (A) and collagenase digestion method reported by Hamada et al. [1] (B) in rats treated with Group B chemicals for 14 or 28 days. Values are presented as the mean and SD. Differences in the incidences of MNHEPs between the test and vehicle control groups were analyzed by the Kastenbaum and Bowman test at significance levels of 5 and 1% (*: P < 0.05, **: P < 0.01). Differences in the incidences of mitotic phase cells between the test and vehicle control groups were analyzed by Dunnett’s multiple comparison test at significance levels of 5 and 1% (#: P < 0.05, ##: P < 0.01). a): Statistically significant but judged as negative because the values were within the range of the background data of negative controls in the laboratory where the MN observation was conducted. Group B: genotoxic carcinogens but not liver targeted
Fig. 3Comparison of RDLMN assay results of formalin-fixed method and collagenase digestion method using Group C chemicals. Incidences of MNHEPs (%); Comparison between formalin-fixed method (A) and collagenase digestion method reported by Hamada et al. [1] (B) in rats treated with Group C chemicals for 14 or 28 days. Values are presented as the mean and SD. Differences in the incidences of MNHEPs between the test and vehicle control groups were analyzed by the Kastenbaum and Bowman test at significance levels of 5 and 1% (*: P < 0.05, **: P < 0.01). Differences in the incidences of mitotic phase cells between the test and vehicle control groups were analyzed by Dunnett’s multiple comparison test at significance levels of 5 and 1% (#: P < 0.05, ##: P < 0.01). Group C: nongenotoxic hepatocarcinogens
Fig. 4Performance of the RDLMN assay: Comparison between formalin-fixed method (A) versus collagenase digestion method (B). The data of collagenase digestion method were reported by Hamada et al. [1]. Sensitivity to hepatocarcinogen (%) = (the number of chemicals that showed positive results in RDLMN assay / the number of hepatocarcinogens tested)× 100. Specificity to non-hepatocarcinogen (%) = (the number of chemicals that showed negative results in RDLMN assay / the number of non-hepatocarcinogens tested)× 100